Healthcare / Drug Manufacturers - Specialty & GenericASX
$0.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-1.5M · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
14/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
188.7%
↑Gross Margin
16.6%
↓Debt/Equity
-0.18
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
-76.5%
FCF CAGR
—
FCF margin
-1144.8%
FCF / Net income
0.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $109965.0 · net income $-2.7M · FCF $-1.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $109965.00 | $109965.00 | $339.00 | $14.4M | $8.5M |
| Net Income | $-2.7M | $-2.7M | $-4.8M | $-3.7M | $-2.8M |
| EBITDA | $-2.1M | $-2.1M | $-2.5M | $-2.6M | $-2.1M |
| EPS | -0.00 | -0.00 | -0.02 | -0.02 | — |
| Gross Margin | 16.6% | 16.6% | 100.0% | 15.9% | 18.2% |
| Operating Margin | -1595.9% | -1595.9% | -740745.1% | -20.6% | -28.3% |
| Net Margin | -2411.5% | -2411.5% | -1424179.4% | -25.7% | -33.1% |
| Balance Sheet | |||||
| Debt/Equity | -0.18 | -0.18 | — | 0.39 | 0.18 |
| Current Ratio | 0.58 | 0.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.3M | $-1.3M | $-1.5M | $-4.9M | $-1.8M |
| Returns | |||||
| ROE | 188.7% | 188.7% | -23979.2% | -115.5% | -53.5% |
| Valuation | |||||
| P/B | — | — | 115.93 | 4.59 | 3.37 |
| Growth & Yield | |||||
| Revenue Growth | 32338.1% | 32338.1% | -100.0% | 68.9% | — |
| EPS Growth | 92.4% | 92.4% | -15.7% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.02 → -0.00
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.